Manufacturer Supply Vildagliptin and Related Intermediates:
Vildagliptin CAS: 274901-16-5
3-Amino-1-Adamantanol CAS: 702-82-9
L-Prolinamide CAS: 7531-52-4
Boc-L-Proline CAS: 15761-39-4
(2S)-1-(Chloroacetyl)-2-Pyrrolidinecarbonitrile CAS: 207557-35-5
| Chemical Name |
Vildagliptin |
| Synonyms |
LAF-237 |
| CAS Number |
274901-16-5 |
| CAT Number |
RF-API30 |
| Stock Status |
In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula |
C17H25N3O2 |
| Molecular Weight |
303.4 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White Crystalline Powder |
| Identification |
IR, HPLC: Must Conform to The Reference Standard |
| Specific Optical Rotation |
-82.0° to -92.0° |
| Melting Point |
148.0~152.0℃ |
| Loss on Drying |
≤0.50% |
| Residue on Ignition |
≤0.10% |
| Heavy Metals |
≤20ppm |
| Sulphate |
≤0.02% |
| Chloride |
≤0.05% |
| Chiral Impurity |
R-Isomer Impurity ≤0.50% |
| Residual Solvents |
|
| Acetonitrile |
≤410ppm |
| Dichloromethane |
≤600ppm |
| Isopropyl Alcohol |
≤5000ppm |
| Related Impurities |
By HPLC |
| Impurity A |
≤0.15% |
| Impurity B |
≤0.15% |
| Impurity C |
≤0.20% |
| Other Single Impurity |
≤0.10% |
| Total Impurities |
≤1.0% |
| Purity / Analysis Method |
≥99.0% (HPLC) |
| Test Standard |
Enterprise Standard |
| Usage |
API, Type 2 Diabetes Mellitus (T2DM) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Vildagliptin (CAS: 274901-16-5) with high quality. Vildagliptin is an oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin was developed by Novartis (Novartis) Pharmaceutical Co., Ltd, is another oral administrated inhibitor of Dipeptidyl peptidase-IV after sitagliptin. In 2008, it is approved for marketing in the European Union for the treatment of type 2 diabetes. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas. Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus.